Summary

• INVEGA SUSTENNA utilizes a nano-particle technology that improves the dissolution of poorly water-soluble compounds. Once in the body, these particles slowly dissolve, gradually releasing a controlled amount of medication consistently over time.¹
• Paliperidone is joined with palmitic acid through ester linkage. Paliperidone palmitate particles are dispersed in an aqueous suspension and transformed into smaller paliperidone palmitate nano-particles through particle-size reduction. Nano-particles have a greater surface area than the larger original particles which results in greater water solubility. Following administration, free paliperidone is slowly released through hydrolysis by esterases in the muscle. Paliperidone is then absorbed into the systemic circulation. Nano-particles allow for rapid achievement of paliperidone concentrations without the need for oral supplementation.¹

LITERATURE SEARCH

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 26 March 2024.